新生血管性AMD抗VEGF治疗不完全应答:机制与治疗机会
本文综述新生血管性年龄相关性黄斑变性(NVAMD)抗VEGF治疗不完全应答(IRT),定义为持续渗出、未消退或新发出血、进行性纤维化及视力恢复欠佳。文章探讨持续疾病活动(PDA)与视力恢复欠佳(SVR)的临床表现和病理生物学,提出动静脉化高流量CNV经新生血管重塑(NVR)形成的假说,并讨论当前管理和未来治疗方向。
要点
- IRT包括持续渗出、出血、纤维化和视力恢复欠佳,前三者合称PDA。
- PDA多见于高流动脉化CNV,毛细血管性CNV对抗VEGF应答较好。
- SVR可能与CNV上方的光感受器突触功能障碍有关,而非单纯变性。
核心结论
- 抗VEGF不完全应答(IRT)包括持续疾病活动(PDA)和视力恢复欠佳(SVR),是NVAMD的重要未满足临床需求。
- PDA与高流动脉化CNV相关,后者可能经新生血管重塑(NVR)机制形成。
- SVR可能与CNV上方神经感觉视网膜的光感受器突触功能障碍相关。
研究设计与样本
- 本文为综述,探讨NVAMD中PDA和SVR的临床表现与病理生物学。
- 综述实验性CNV研究,指出两类CNV均可在小鼠中建模。
主要发现
- PDA最常见于发生高流动脉化CNV病变的NVAMD患者,而毛细血管性CNV患者对抗VEGF治疗高度应答。
- 提出假说:动脉化CNV通过NVR形成,血液来源巨噬细胞浸润初发CNV病变,招募骨髓来源间充质前体细胞(MPC),并激活MPC成为血管平滑肌细胞(VSMC)和肌纤维母细胞,驱动高流量CNV伴动脉化及血管周围纤维化。
- SVR可能并非单纯由光感受器变性所致,而与CNV上方神经感觉视网膜的光感受器突触功能障碍相关,由浸润的血液来源巨噬细胞触发、经Müller细胞激活介导。
关键数值与推荐
- IRT定义为:(1)持续(血浆)渗出;(2)未消退或新发出血;(3)进行性病变纤维化;和/或(4)视力恢复欠佳。
- 前三条合称抗VEGF治疗下的持续疾病活动(PDA)。
- 视力恢复欠佳(SVR)定义为尽管充分抗VEGF治疗仍未能达到20/40或更好的优良功能视力。
临床怎么用
- 对PDA患者应识别高流动脉化CNV表型,其对抗VEGF应答可能不佳。
- 对SVR患者需考虑光感受器突触功能障碍机制,而非仅归因于变性。
- 针对PDA和SVR应探索当前疾病管理与新型未来治疗途径。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Intravitreal anti-vascular endothelial growth factor (VEGF) drugs have revolutionized the treatment of neovascular age-related macular degeneration (NVAMD). However, many patients suffer from incomplete response to anti-VEGF therapy (IRT), which is defined as (1) persistent (plasma) fluid exudation; (2) unresolved or new hemorrhage; (3) progressive lesion fibrosis; and/or (4) suboptimal vision recovery. The first three of these collectively comprise the problem of persistent disease activity (PDA) in spite of anti-VEGF therapy. Meanwhile, the problem of suboptimal vision recovery (SVR) is defined as a failure to achieve excellent functional visual acuity of 20/40 or better in spite of sufficient anti-VEGF treatment. Thus, incomplete response to anti-VEGF therapy, and specifically PDA and SVR, represent significant clinical unmet needs. In this review, we will explore PDA and SVR in NVAMD, characterizing the clinical manifestations and exploring the pathobiology of each. We will demonstrate that PDA occurs most frequently in NVAMD patients who develop high-flow CNV lesions with arteriolarization, in contrast to patients with capillary CNV who are highly responsive to anti-VEGF therapy. We will review investigations of experimental CNV and demonstrate that both types of CNV can be modeled in mice. We will present and consider a provocative hypothesis: formation of arteriolar CNV occurs via a distinct pathobiology, termed neovascular remodeling (NVR), wherein blood-derived macrophages infiltrate the incipient CNV lesion, recruit bone marrow-derived mesenchymal precursor cells (MPCs) from the circulation, and activate MPCs to become vascular smooth muscle cells (VSMCs) and myofibroblasts, driving the development of high-flow CNV with arteriolarization and perivascular fibrosis. In considering SVR, we will discuss the concept that limited or poor vision in spite of anti-VEGF may not be caused simply by photoreceptor degeneration but instead may be associated with photoreceptor synaptic dysfunction in the neurosensory retina overlying CNV, triggered by infiltrating blood-derived macrophages and mediated by Müller cell activation Finally, for each of PDA and SVR, we will discuss current approaches to disease management and treatment and consider novel avenues for potential future therapies.
引用
- Mettu PS, Allingham MJ, Cousins SW, et al. Incomplete response to Anti-VEGF therapy in neovascular AMD: Exploring disease mechanisms and therapeutic opportunities. Prog Retin Eye Res. 2020. PMID: 33022379. doi:10.1016/j.preteyeres.2020.100906
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。